Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Trading Update

6 Jan 2005 07:00

Torex Retail PLC06 January 2005 6 January 2005 TOREX RETAIL PLC TRADING UPDATE Torex Retail plc ("Torex Retail" or "the Group"), the UK's market leader inretail IT solutions, is pleased to announce that following the close of its yearend on 31 December 2004, it expects to report pre-tax profits ahead ofexpectations when it announces its preliminary results in February 2005. This reflects strong trading from all areas of the Group. The success of theGroup in the second half of 2004 is based upon sales of Group software productswith associated services, particularly with new contract wins for its marketleading EpoS product LUCAS. This has reinforced the changing business modelexperienced in the first half with increased software licence sales and lowerhardware revenues contributing to improved operating margins. In addition atight control on working capital has resulted in a strong cash inflow fromoperating activities. The integration of Alphameric Retail has commenced and initial findings areconsistent with pre-acquisition due diligence and the strategic rationale forthe transaction. In addition, new opportunities are being identified which isvery encouraging for 2005 and beyond. Rob Loosemore, Chairman of Torex Retail plc, commented: "I am delighted with the progress we have made in our first year as a publiccompany both in terms of financial performance and strategic development.Strong trading, particularly in the second half, together with the acquisitionof Alphameric's Retail Division provides a tremendous platform and momentum fororganic growth in 2005 and beyond. The pre-tax profits will be ahead ofexpectations which continues the long established tradition of the seniormanagement team, of not only doing what we say we will do but exceeding it." Enquiries: Torex Retail plc Citigate Dewe Rogerson Mark Pearman, Chief Executive Ginny Pulbrook / Seb Hoyle / Freida Moore Richard Thompson, Finance Director Telephone: +44 (0)20 7638 9571 Telephone: +44 (0)870 050 9900 Notes to Editors: Torex Retail, a leading European retail solutions business, floated on AIM inMarch 2004. The business is an independent supplier of electronic point of sale("EPOS") solutions and services and productivity tools to high street,convenience and petroleum retailers with an installed base of some 50,000 EPOSlicences across Europe. It has a broad base of blue-chip clients and employs700 staff in UK, Germany, Belgium, Holland and Eire. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Nov 20249:32 amRNSForm 8.3 - Tissue Regenix Group Plc
12th Nov 20244:05 pmRNSForm 8 (OPD) (Tissue Regenix Group Plc)
12th Nov 20248:46 amRNSForm 8.5 (EPT/NON-RI)
11th Nov 20249:17 amRNSForm 8.5 (EPT/NON-RI)
7th Nov 20249:59 amRNSForm 8.5 (EPT/NON-RI) - Tissue Regenix Group PLC
6th Nov 20241:37 pmRNSForm 8.3 - Tissue Regenix Group PLC
6th Nov 20248:52 amRNSForm 8.5 (EPT/NON-RI)
5th Nov 20242:24 pmRNSForm 8.3 - Tissue Regenix Group PLC
5th Nov 202411:32 amRNSForm 8.5 (EPT/NON-RI)
4th Nov 20244:36 pmRNSResponse to media speculation
10th Sep 20247:00 amRNSInterim results for the six months ended 30 June
18th Jul 20243:52 pmRNSGrant of share options
16th Jul 20247:00 amRNSHalf-Year Trading Update
3rd Jul 20241:16 pmRNSHolding(s) in Company
24th Jun 20244:12 pmRNSHolding(s) in Company
18th Jun 20245:15 pmRNSExercise of Options, Director Dealing and TVR
14th Jun 20247:00 amRNSBuilding purchase
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.